A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell carcinoma (BCC) may benefit from receiving immunotherapy earlier in the course of ...
From 20-30% of patients with advanced basal cell carcinoma (BCC) responded to the PD-1 inhibitor cemiplimab (Libtayo) after resistance or intolerance to a hedgehog-pathway inhibitor, according to ...
A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell carcinoma (BCC) may benefit from receiving immunotherapy earlier in the course of ...
Nearly half of people diagnosed with advanced cancer over a recent 5-year period did not undergo next-generation sequencing, according to results of a retrospective cohort study.Rates improved over ...
Durable, ongoing near-complete response to nivolimab + relatlimab in a 64 year old with locally-advanced BCC after resistance to 26 wks of nivolimab alone. A new study led by researchers at the Johns ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results